重组凝血因子VIII-SingleChain在重型血友病A患者中的群体药代动力学
基于130例重型血友病A患者单次50 IU/kg rVIII-SingleChain的药代动力学数据建立二室群体药代动力学模型,体重和给药前血管性血友病因子水平是清除率的显著协变量,模拟显示每周三次给药可使超过85%患者维持FVIII活性高于1 IU/dL。
要点
- 二室群体药代动力学模型充分描述rVIII-SingleChain的FVIII活性。
- 体重和给药前血管性血友病因子水平是清除率的显著协变量。
- 模拟支持rVIII-SingleChain延长给药间隔至每周两次。
核心结论
- 群体药代动力学模型充分表征rVIII-SingleChain的药代动力学,可用于模拟不同给药方案的FVIII活性-时间曲线。
研究设计与样本
- 基于130例重型血友病A患者(≥12-65岁91例,<12岁39例)单次50 IU/kg rVIII-SingleChain药代动力学研究的FVIII活性水平建立群体药代动力学模型,PK采样至96小时。
主要发现
- 二室群体药代动力学模型加一阶消除充分描述FVIII活性。
- 体重和给药前血管性血友病因子水平是清除率的显著协变量,体重是中央分布容积的显著协变量。
- 每周三次给药(第0、2、4.5天)最低剂量20 IU/kg时预测超过85%患者维持FVIII活性高于1 IU/dL,最高剂量50 IU/kg时预测超过93%患者维持FVIII活性高于1 IU/dL。
- 每周两次给药(第0、3.5天)50 IU/kg rVIII-SingleChain时,所有年龄患者中62-80%预测在第7天维持FVIII活性高于1 IU/dL。
临床怎么用
- 模型支持rVIII-SingleChain延长给药间隔至每周两次。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
UNLABELLED: Essentials rVIII-SingleChain is a unique recombinant factor VIII (FVIII) molecule. A population pharmacokinetic model was based on FVIII activity of severe hemophilia A patients. The model was used to simulate factor VIII activity-time profiles for various dosing scenarios. The model supports prolonged dosing of rVIII-SingleChain with intervals of up to twice per week. SUMMARY: Background Single-chain recombinant coagulation factor VIII (rVIII-SingleChain) is a unique recombinant coagulation factor VIII molecule. Objectives To: (i) characterize the population pharmacokinetics (PK) of rVIII-SingleChain in patients with severe hemophilia A; (ii) identify correlates of variability in rVIII-SingleChain PK; and (iii) simulate various dosing scenarios of rVIII-SingleChain. Patients/Methods A population PK model was developed, based on FVIII activity levels of 130 patients with severe hemophilia A (n = 91 for ≥ 12-65 years; n = 39 for < 12 years) who had participated in a single-dose PK investigation with rVIII-SingleChain 50 IU kg-1 . PK sampling was performed for up to 96 h. Results A two-compartment population PK model with first-order elimination adequately described FVIII activity. Body weight and predose level of von Willebrand factor were significant covariates on clearance, and body weight was a significant covariate on the central distribution volume. Simulations using the model with various dosing scenarios estimated that > 85% and > 93% of patients were predicted to maintain FVIII activity level above 1 IU dL-1 , at all times with three-times-weekly dosing (given on days 0, 2, and 4.5) at the lowest (20 IU kg-1 ) and highest (50 IU kg-1 ) doses, respectively. For twice weekly dosing (days 0 and 3.5) of 50 IU kg-1 rVIII-SingleChain, 62-80% of patients across all ages were predicted to maintain a FVIII activity level above 1 IU dL-1 at day 7. Conclusions The population PK model adequately characterized rVIII-SingleChain PK, and the model can be utilized to simulate FVIII activity-time profiles for various dosing scenarios.
引用
- Zhang Y, Roberts J, Tortorici M, et al. Population pharmacokinetics of recombinant coagulation factor VIII-SingleChain in patients with severe hemophilia A. J Thromb Haemost. 2017. PMID: 28244200. doi:10.1111/jth.13662
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。